Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

NPS Says It Hasn’t Heard From Shire About Potential Deal

Don't Miss Out —
Follow us on:

June 2 (Bloomberg) -- NPS Pharmaceuticals Inc. said it hasn’t received any overtures from Shire Plc or any of the Dublin-based drug company’s representatives about a possible acquisition.

Bloomberg News reported May 30 that NPS hadn’t been contacted by Shire, according to a personal familiar with the matter. The Financial Times’ Alphaville website reported on May 30 that Shire has held internal discussions about a possible cash offer for NPS, the Bedminster, New Jersey-based company that makes medicines for rare diseases. Shire has been adding drugs for rare diseases to lessen its dependence on its best-selling pill for attention deficit hyperactivity disorder.

NPS hasn’t been approached about a potential takeover, the company said today in a filing with the Securities and Exchange Commission.

NPS said it released the statement because of “erroneous press reports” that Shire had communicated with the company. NPS said it will return to its policy of not commenting on rumors or speculation, and makes no promises to update the information it provided today to regulators.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at

To contact the editors responsible for this story: Reg Gale at Andrew Pollack, John Lear

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.